Revolutionizing Cancer Biopsies with Point-of-Care Testing Solutions
ROSE Diagnostics’ inventive technology has been designed to significantly improve the success rate of lung cancer biopsies. It’s our mission to reduce the cost and time it takes for a patient to receive a lung cancer diagnosis, leading to the start of treatment faster.
Up to 40% of the time, lung biopsy samples are returned as insufficient for analysis.
During a typical cancer biopsy, collected specimens are sent to a pathology lab to verify the correct tissue was collected for an analysis and diagnosis. When that tissue sample is insufficient for analysis, the patient has to come in for another biopsy, repeating the process.
With ROSE Diagnostics technology, specimens can be tested during the biopsy procedure; reducing or eliminating the need for another biopsy.
We’ve created a rapid 5 minute test that drives real-time actionable decisions.
ROSE Diagnostics is developing a panel of known lymph node biomarkers in a rapid point-of-care test format. Disposable test cartridges are read on an affordable, small and portable reader already approved for other diagnostic products.
*Products not FDA cleared or approved in any jurisdiction
Improving the patient journey
Getting a cancer diagnosis is a stressful and scary process.
We believe we can eliminate the risk of an insufficient biopsy, so patients can get a diagnosis as quickly as possible.
A successful biopsy the first time around saves time, medical costs, and the anxiety of waiting for a diagnosis.
Lung cancer is the leading cause of cancer deaths in the U.S., with 225,000 new cases annually. We believe these patients should be recieiving critical treatment instead of waiting for a diagnosis.
